The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Rationale: There is currently no effective pharmacological treatment for obstructive sleep apnea (OSA). Recent investigations indicate that drugs with noradrenergic and antimuscarinic effects improve genioglossus muscle activity and upper airway patency during sleep. Objectives: We aimed to determine the effects of the combination of a norepinephrine reuptake inhibitor (atomoxetine) and an antimuscarinic (oxybutynin) on OSA severity (apnea–hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (secondary outcome) in people with OSA. Methods: A total of 20 people completed a randomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine plus 5 mg oxybutynin (ato–oxy) to placebo administered before sleep. The AHI and genioglossus muscle responsiveness to negative esophageal pressure swings were measured via in-laboratory polysomnography. In a subgroup of nine patients, the AHI was also measured when the drugs were administered separately. Measurements and Main Results: The participants’ median (interquartile range) age was 53 (46–58) years and body mass index was 34.8 (30.0–40.2) kg/m2. ato–oxy lowered AHI by 63% (34–86%), from 28.5 (10.9–51.6) events/h to 7.5 (2.4–18.6) events/h (P < 0.001). Of the 15/20 patients with OSA on placebo (AHI > 10 events/hr), AHI was lowered by 74% (62–88%) (P < 0.001) and all 15 patients exhibited a ≥50% reduction. Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1–4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato–oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately. Conclusions: A combination of noradrenergic and antimuscarinic agents administered orally before bedtime on 1 night greatly reduced OSA severity. These findings open new possibilities for the pharmacologic treatment of OSA. Clinical trial registered with www.clinicaltrials.gov (NCT02908529).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A recent pilot study showed potential benefits of the combination of oxybutynin and atomoxetine on the AHI.”
From International Consensus Statement on Obstructive Sleep Apnea (2023) · cites this paper as [393]
The cited source says what the claim attributes to it.
In the citing paper
“Inadequate upper airway dilating muscle compensation may be improved by targeted pharmacotherapy (Taranto‐Montemurro et al., 2019).”
From Obstructive sleep apnea: transition from pathophysiology to an integrative disease model (2022) · cites this paper as Taranto-Montemurro et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berry, R. B., Budhiraja, R., Gottlieb, D. J., Gozal, D., Iber, C., Kapur, V. K., Marcus, C. L., Mehra, R., Parthasarathy, S., Quan, S. F., et al. (2012) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.2172 · Cited by 5,302
Increased Prevalence of Sleep-Disordered Breathing in Adults
Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws342 · Cited by 4,618 · cited 4×
“Obstructive sleep apnea (OSA) is a common disorder that occurs in 6% of women and 13% of men in the United States (1).”
BackgroundInfluentialMcNicholas, W. T., Strohl, K. P., White, D. P., Levy, P. A., Schmidt, W., Wheatley, J. R., Redline, S. S., Carley, D. W., Buysse, D. J., Young, T. B., et al. (1999) · PubMed · Cited by 3,665
Self-citationSullivan, C., Berthon-Jones, M., Issa, F., & Eves, L. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92140-1 · Cited by 2,731 · cited 4×
“Although CPAP is virtually always efficacious, because it mechanically splints the airway open, limited adherence to this treatment remains a major problem (4).”
BackgroundInfluentialUpper-Airway Stimulation for Obstructive Sleep Apnea
Strollo, P. J., Soose, R. J., Maurer, J. T., de Vries, N., Cornelius, J., Froymovich, O., Hanson, R. D., Padhya, T. A., Steward, D. L., Gillespie, M. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308659 · Cited by 1,299
Defining Phenotypic Causes of Obstructive Sleep Apnea. Identification of Novel Therapeutic Targets
Eckert, D. J., White, D. P., Jordan, A. S., Malhotra, A., & Wellman, A. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201303-0448oc · Cited by 1,173 · cited 3×
“In the presence of an anatomical predisposition, a reduced responsiveness of the upper airway dilator muscles—including the genioglossus—during sleep promotes the collapse of pharyngeal structures, with ensuing episodes of reduced ventilation, intermittent hypoxia, hypercapnia, and arousals from sleep (2).”
BackgroundSelf-citationSawyer, A. M., Gooneratne, N. S., Marcus, C. L., Ofer, D., Richards, K. C., & Weaver, T. E. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2011.01.003 · Cited by 900 · cited 1×
“Although CPAP is virtually always efficacious, because it mechanically splints the airway open, limited adherence to this treatment remains a major problem (4).”
BackgroundAzarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893 · cited 2×
“The OSA-specific hypoxic burden (27) was 28.”
MethodSelf-citationPhillips, C. L., Grunstein, R. R., Darendeliler, M. A., Mihailidou, A. S., Srinivasan, V. K., Yee, B. J., Marks, G. B., & Cistulli, P. A. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2223oc · Cited by 572 · cited 2×
“5) OSA treatment, n (%) CPAP compliant 5 (25) CPAP noncompliant 5 (25) Oral appliance 1 (5) None 9 (45) Comorbidities, n (%) Hypertension 7 (35) Diabetes 2 (10) Hypercholesterolemia 3 (15) Medications, n (%) ACE-I/ARB 5 (25) Ca(21) antagonists 3 (15) b-Blockers 2 (10) Spironolactone 2 (10) HCTZ 1 (5) Antilipidemic 3 (…”
Background
Cited by
Diagnosis and Management of Obstructive Sleep Apnea: A Review
Gottlieb, D. J., & Punjabi, N. M. (2020) · JAMA · doi:10.1001/jama.2020.3514 · Cited by 1,482
Obstructive Sleep Apnea in Adults
Veasey, S. C., & Rosen, I. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816152 · Cited by 615
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome
Lv, R., Liu, X., Zhang, Y., Dong, N., Wang, X., He, Y., Yue, H., & Yin, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01496-3 · Cited by 477
International Consensus Statement on Obstructive Sleep Apnea
Chang, J. L., Goldberg, A. N., Alt, J. A., Mohammed, A., Ashbrook, L., Auckley, D., Ayappa, I., Bakhtiar, H., Barrera, J. E., Bartley, B. L., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23079 · Cited by 350
Evaluation and Management of Adults with Obstructive Sleep Apnea Syndrome
Lee, J. J., & Sundar, K. M. (2021) · Lung · doi:10.1007/s00408-021-00426-w · Cited by 230
“While two recent studies, one using a combination of atomoxetine and oxybutynin [113] and another using a cannabinoid [114], both showed impressive results with regard to AHI reduction, their patient population was smalland larger-scale trials evaluating side effects as well as both short-term and long-term treatment…”
Result
Metadata
- Authors
- Taranto-Montemurro, L., Messineo, L., Sands, S. A., Azarbarzin, A., Marques, M., Edwards, B. A., Eckert, D. J., White, D. P., & Wellman, A.
- Affiliations
- Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham & Women's Hospital & Harvard Medical School, Boston, Massachusetts
- Brigham and Women's Hospital (US)
- Monash University (AU)
- UNSW Sydney (AU)
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05
- Volume
- 199
- Issue
- 10
- Pages
- 1267-1276
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC6519859
- OpenAlex
- W2900097455
- Semantic Scholar
- f798b0226fe357af9b0b29a46d21a34bbeaec0b8
- Cited by
- 297
- References
- 38
- Citations by year
- 2026: 38 · 2025: 28 · 2024: 43 · 2023: 50 · 2022: 53 · 2021: 35 · 2020: 24 · 2019: 25
- FWCI
- 14.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- OMPA Corporation, Kaifeng, China (R01HL102321, P01HL095491, UL1RR025758-01)
- American Heart Association (17POST33410436 (L.T.-M.), 15SDG25890059)
- University of Brescia scholarship
- National Health and Medical Research Council
- Martin Overseas Biomedical Fellowship (1035115)
- Heart Foundation of Australia Future Leader Fellowship (101167 (B.A.E.))
- NHMRC Early Career (1053201)
- Menzies Foundation, and the American Thoracic Society Foundation
- NHMRC Senior Research Fellowship (1116942 (D.J.E.).)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroscience of respiration and sleep
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- obstructive sleep apnea, atomoxetine, oxybutynin, combination therapy, norepinephrine reuptake inhibitors, apnea-hypopnea index, upper airway patency, esophageal pressure
- MeSH terms
- Atomoxetine Hydrochloride, Double-Blind Method, Drug Combinations, Female, Humans, Male, Mandelic Acids, Middle Aged, Parasympatholytics, Sleep, Placebo Effect, Cross-Over Studies, Adrenergic Uptake Inhibitors, Sleep Apnea, Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial. https://app.cochat.ai/papers/10.1164/rccm.201808-1493oc
- The paper
- Taranto-Montemurro, L., Messineo, L., Sands, S. A., Azarbarzin, A., Marques, M., Edwards, B. A., Eckert, D. J., White, D. P., & Wellman, A. (2019). The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201808-1493oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.